On November 2, 2021 Philogen S.p.A., a clinical-stage biotechnology company focused on antibody-and small molecule-based targeted therapeutics, reported that it will announce its Third Quarter 2021 Results for the three months ended 30th September 2021 following a Board of Director’s meeting to be held on Thursday 11th November 2021 (Press release, Philogen, NOV 2, 2021, View Source [SID1234594092]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Prof. Dr. Dario Neri, Chief Executive Officer, Dr. Laura Baldi, Chief Financial Officer, Dr. Christian Lizak, and Dr. Emanuele Puca will host a virtual briefing for sell-side analysts at 11 am EST / 4 pm GMT / 5 pm CEST on Friday 12th November 2021.

For more details or to attend the virtual briefing, please contact [email protected].